APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endogenous Neuromodulation Platform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Endogenous Neuromodulation Platform Market Outlook and Growth Opportunities 2026

5 June 2026208 pages

Choose your research edition.

Industry ResearchEndogenous Neuromodulation Platform Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Endogenous Neuromodulation Platform Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Endogenous Neuromodulation Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endogenous Neuromodulation Platform Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Endogenous Neuromodulation Platform Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Endogenous Neuromodulation Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Endogenous Neuromodulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Endogenous Neuromodulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Endogenous Neuromodulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Endogenous Neuromodulation Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Endogenous Neuromodulation Platform market include Medtronic, Abbott, Boston Scientific, NeuroPace, ElectroCore, Neuronetics, LivaNova, Magstim and Sooma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Endogenous Neuromodulation Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Endogenous Neuromodulation Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Endogenous Neuromodulation Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Endogenous Neuromodulation Platform market.

Endogenous Neuromodulation Platform Segment by Company

Medtronic

Abbott

Boston Scientific

NeuroPace

ElectroCore

Neuronetics

LivaNova

Magstim

Sooma

Neuroelectrics

Flow Neuroscience

ONWARD Medical

PINS Medical

SceneRay

Yingchi Technology

Yiruide

Neuracle

BrainCo

Cyberdyne

Teijin Pharma

Endogenous Neuromodulation Platform Segment by Type

Chemical Molecular Regulation Platform

Bioengineering Regulation Platform

Endogenous Neuromodulation Platform Segment by Application

Hospital

Clinic

Others

Endogenous Neuromodulation Platform Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Endogenous Neuromodulation Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Endogenous Neuromodulation Platform key companies, revenue, market share, and recent developments.

3. To split the Endogenous Neuromodulation Platform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Endogenous Neuromodulation Platform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Endogenous Neuromodulation Platform significant trends, drivers, influence factors in global and regions.

6. To analyze Endogenous Neuromodulation Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endogenous Neuromodulation Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endogenous Neuromodulation Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endogenous Neuromodulation Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endogenous Neuromodulation Platform industry.

Chapter 3: Detailed analysis of Endogenous Neuromodulation Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Endogenous Neuromodulation Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Endogenous Neuromodulation Platform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Endogenous Neuromodulation Platform Industry Trends Table 2. Endogenous Neuromodulation Platform Industry Drivers Table 3. Endogenous Neuromodulation Platform Industry Opportunities and Challenges Table 4. Endogenous Neuromodulation Platform Industry Restraints Table 5. Global Endogenous Neuromodulation Platform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Endogenous Neuromodulation Platform Revenue Share by Company (2021-2026) Table 7. Global Endogenous Neuromodulation Platform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Endogenous Neuromodulation Platform Key Company Manufacturing Base & Headquarters Table 9. Global Endogenous Neuromodulation Platform Company, Product Type & Application Table 10. Global Endogenous Neuromodulation Platform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Endogenous Neuromodulation Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chemical Molecular Regulation Platform Table 15. Significant Companies of Bioengineering Regulation Platform Table 16. Global Endogenous Neuromodulation Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Endogenous Neuromodulation Platform Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Endogenous Neuromodulation Platform Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Endogenous Neuromodulation Platform Sales Value Share by Type (2021-2026) Table 20. Global Endogenous Neuromodulation Platform Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Endogenous Neuromodulation Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Endogenous Neuromodulation Platform Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Endogenous Neuromodulation Platform Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Endogenous Neuromodulation Platform Sales Value Share by Application (2021-2026) Table 28. Global Endogenous Neuromodulation Platform Sales Value Share by Application (2027-2032) Table 29. Global Endogenous Neuromodulation Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Endogenous Neuromodulation Platform Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Endogenous Neuromodulation Platform Sales Value Share by Region (2021-2026) Table 32. Global Endogenous Neuromodulation Platform Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Endogenous Neuromodulation Platform Sales Value Share by Region (2027-2032) Table 34. Global Endogenous Neuromodulation Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Endogenous Neuromodulation Platform Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Endogenous Neuromodulation Platform Sales Value Market Share by Country (2021-2026) Table 37. Global Endogenous Neuromodulation Platform Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Endogenous Neuromodulation Platform Sales Value Market Share by Country (2027-2032) Table 39. Medtronic Company Information Table 40. Medtronic Business Overview Table 41. Medtronic Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Medtronic Endogenous Neuromodulation Platform Product Portfolio Table 43. Medtronic Recent Development Table 44. Abbott Company Information Table 45. Abbott Business Overview Table 46. Abbott Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Abbott Endogenous Neuromodulation Platform Product Portfolio Table 48. Abbott Recent Development Table 49. Boston Scientific Company Information Table 50. Boston Scientific Business Overview Table 51. Boston Scientific Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Boston Scientific Endogenous Neuromodulation Platform Product Portfolio Table 53. Boston Scientific Recent Development Table 54. NeuroPace Company Information Table 55. NeuroPace Business Overview Table 56. NeuroPace Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. NeuroPace Endogenous Neuromodulation Platform Product Portfolio Table 58. NeuroPace Recent Development Table 59. ElectroCore Company Information Table 60. ElectroCore Business Overview Table 61. ElectroCore Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. ElectroCore Endogenous Neuromodulation Platform Product Portfolio Table 63. ElectroCore Recent Development Table 64. Neuronetics Company Information Table 65. Neuronetics Business Overview Table 66. Neuronetics Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Neuronetics Endogenous Neuromodulation Platform Product Portfolio Table 68. Neuronetics Recent Development Table 69. LivaNova Company Information Table 70. LivaNova Business Overview Table 71. LivaNova Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. LivaNova Endogenous Neuromodulation Platform Product Portfolio Table 73. LivaNova Recent Development Table 74. Magstim Company Information Table 75. Magstim Business Overview Table 76. Magstim Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Magstim Endogenous Neuromodulation Platform Product Portfolio Table 78. Magstim Recent Development Table 79. Sooma Company Information Table 80. Sooma Business Overview Table 81. Sooma Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sooma Endogenous Neuromodulation Platform Product Portfolio Table 83. Sooma Recent Development Table 84. Neuroelectrics Company Information Table 85. Neuroelectrics Business Overview Table 86. Neuroelectrics Endogenous Neuromodulation Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Neuroelectrics Endogenous Neuromodulation Platform Product Portfolio Table 88. Neuroelectrics Recent Development Table 89. Flow Neuroscience Company Information Table 90. Flow Neuroscience Business Overview Table 91. Flow Neuroscience Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Flow Neuroscience Endogenous Neuromodulation Platform Product Portfolio Table 93. Flow Neuroscience Recent Development Table 94. ONWARD Medical Company Information Table 95. ONWARD Medical Business Overview Table 96. ONWARD Medical Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. ONWARD Medical Endogenous Neuromodulation Platform Product Portfolio Table 98. ONWARD Medical Recent Development Table 99. PINS Medical Company Information Table 100. PINS Medical Business Overview Table 101. PINS Medical Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. PINS Medical Endogenous Neuromodulation Platform Product Portfolio Table 103. PINS Medical Recent Development Table 104. SceneRay Company Information Table 105. SceneRay Business Overview Table 106. SceneRay Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. SceneRay Endogenous Neuromodulation Platform Product Portfolio Table 108. SceneRay Recent Development Table 109. Yingchi Technology Company Information Table 110. Yingchi Technology Business Overview Table 111. Yingchi Technology Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Yingchi Technology Endogenous Neuromodulation Platform Product Portfolio Table 113. Yingchi Technology Recent Development Table 114. Yiruide Company Information Table 115. Yiruide Business Overview Table 116. Yiruide Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Yiruide Endogenous Neuromodulation Platform Product Portfolio Table 118. Yiruide Recent Development Table 119. Neuracle Company Information Table 120. Neuracle Business Overview Table 121. Neuracle Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Neuracle Endogenous Neuromodulation Platform Product Portfolio Table 123. Neuracle Recent Development Table 124. BrainCo Company Information Table 125. BrainCo Business Overview Table 126. BrainCo Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. BrainCo Endogenous Neuromodulation Platform Product Portfolio Table 128. BrainCo Recent Development Table 129. Cyberdyne Company Information Table 130. Cyberdyne Business Overview Table 131. Cyberdyne Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. Cyberdyne Endogenous Neuromodulation Platform Product Portfolio Table 133. Cyberdyne Recent Development Table 134. Teijin Pharma Company Information Table 135. Teijin Pharma Business Overview Table 136. Teijin Pharma Endogenous Neuromodulation Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Teijin Pharma Endogenous Neuromodulation Platform Product Portfolio Table 138. Teijin Pharma Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Endogenous Neuromodulation Platform Product Image Figure 2. Global Endogenous Neuromodulation Platform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endogenous Neuromodulation Platform Market Size (2021-2032) & (US$ Million) Figure 4. Global Endogenous Neuromodulation Platform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chemical Molecular Regulation Platform Image Figure 8. Bioengineering Regulation Platform Image Figure 9. Global Endogenous Neuromodulation Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Endogenous Neuromodulation Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Endogenous Neuromodulation Platform Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Endogenous Neuromodulation Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Endogenous Neuromodulation Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Endogenous Neuromodulation Platform Sales Value Share by Application (2021-2032) Figure 18. Global Endogenous Neuromodulation Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Endogenous Neuromodulation Platform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Endogenous Neuromodulation Platform Sales Value (2021-2032) & (US$ Million) Figure 21. North America Endogenous Neuromodulation Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Endogenous Neuromodulation Platform Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Endogenous Neuromodulation Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Endogenous Neuromodulation Platform Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Endogenous Neuromodulation Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Endogenous Neuromodulation Platform Sales Value (2021-2032) & (US$ Million) Figure 27. South America Endogenous Neuromodulation Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Endogenous Neuromodulation Platform Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Endogenous Neuromodulation Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Chemical Molecular Regulation Platform
  • Bioengineering Regulation Platform
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Medtronic
  • Abbott
  • Boston Scientific
  • NeuroPace
  • ElectroCore
  • Neuronetics
  • LivaNova
  • Magstim
  • Sooma
  • Neuroelectrics
  • Flow Neuroscience
  • ONWARD Medical
  • PINS Medical
  • SceneRay
  • Yingchi Technology
  • Yiruide
  • Neuracle
  • BrainCo
  • Cyberdyne
  • Teijin Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Endogenous Neuromodulation Platform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Endogenous Neuromodulation Platform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Endogenous Neuromodulation Platform Market Dynamics
  1. 2.1 Endogenous Neuromodulation Platform Industry Trends
  2. 2.2 Endogenous Neuromodulation Platform Industry Drivers
  3. 2.3 Endogenous Neuromodulation Platform Industry Opportunities and Challenges
  4. 2.4 Endogenous Neuromodulation Platform Industry Restraints
3 Endogenous Neuromodulation Platform Market by Company
  1. 3.1 Global Endogenous Neuromodulation Platform Company Revenue Ranking in 2025
  2. 3.2 Global Endogenous Neuromodulation Platform Revenue by Company (2021-2026)
  3. 3.3 Global Endogenous Neuromodulation Platform Company Ranking (2024-2026)
  4. 3.4 Global Endogenous Neuromodulation Platform Company Manufacturing Base and Headquarters
  5. 3.5 Global Endogenous Neuromodulation Platform Company Product Type and Application
  6. 3.6 Global Endogenous Neuromodulation Platform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Endogenous Neuromodulation Platform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Endogenous Neuromodulation Platform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Endogenous Neuromodulation Platform Market by Type
  1. 4.1 Endogenous Neuromodulation Platform Type Introduction
  2. 4.1.1 Chemical Molecular Regulation Platform
  3. 4.1.2 Bioengineering Regulation Platform
  4. 4.2 Global Endogenous Neuromodulation Platform Sales Value by Type
  5. 4.2.1 Global Endogenous Neuromodulation Platform Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Endogenous Neuromodulation Platform Sales Value by Type (2021-2032)
  7. 4.2.3 Global Endogenous Neuromodulation Platform Sales Value Share by Type (2021-2032)
5 Endogenous Neuromodulation Platform Market by Application
  1. 5.1 Endogenous Neuromodulation Platform Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Endogenous Neuromodulation Platform Sales Value by Application
  6. 5.2.1 Global Endogenous Neuromodulation Platform Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Endogenous Neuromodulation Platform Sales Value by Application (2021-2032)
  8. 5.2.3 Global Endogenous Neuromodulation Platform Sales Value Share by Application (2021-2032)
6 Endogenous Neuromodulation Platform Regional Value Analysis
  1. 6.1 Global Endogenous Neuromodulation Platform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Endogenous Neuromodulation Platform Sales Value by Region (2021-2032)
  3. 6.2.1 Global Endogenous Neuromodulation Platform Sales Value by Region: 2021-2026
  4. 6.2.2 Global Endogenous Neuromodulation Platform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Endogenous Neuromodulation Platform Sales Value (2021-2032)
  7. 6.3.2 North America Endogenous Neuromodulation Platform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Endogenous Neuromodulation Platform Sales Value (2021-2032)
  10. 6.4.2 Europe Endogenous Neuromodulation Platform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Endogenous Neuromodulation Platform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Endogenous Neuromodulation Platform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Endogenous Neuromodulation Platform Sales Value (2021-2032)
  16. 6.6.2 South America Endogenous Neuromodulation Platform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Endogenous Neuromodulation Platform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Endogenous Neuromodulation Platform Sales Value Share by Country, 2025 VS 2032
7 Endogenous Neuromodulation Platform Country-level Value Analysis
  1. 7.1 Global Endogenous Neuromodulation Platform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Endogenous Neuromodulation Platform Sales Value by Country (2021-2032)
  3. 7.2.1 Global Endogenous Neuromodulation Platform Sales Value by Country (2021-2026)
  4. 7.2.2 Global Endogenous Neuromodulation Platform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Endogenous Neuromodulation Platform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Endogenous Neuromodulation Platform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Endogenous Neuromodulation Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Medtronic
  2. 8.1.1 Medtronic Company Information
  3. 8.1.2 Medtronic Business Overview
  4. 8.1.3 Medtronic Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Medtronic Endogenous Neuromodulation Platform Product Portfolio
  6. 8.1.5 Medtronic Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Endogenous Neuromodulation Platform Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Boston Scientific
  14. 8.3.1 Boston Scientific Company Information
  15. 8.3.2 Boston Scientific Business Overview
  16. 8.3.3 Boston Scientific Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boston Scientific Endogenous Neuromodulation Platform Product Portfolio
  18. 8.3.5 Boston Scientific Recent Developments
  19. 8.4 NeuroPace
  20. 8.4.1 NeuroPace Company Information
  21. 8.4.2 NeuroPace Business Overview
  22. 8.4.3 NeuroPace Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 NeuroPace Endogenous Neuromodulation Platform Product Portfolio
  24. 8.4.5 NeuroPace Recent Developments
  25. 8.5 ElectroCore
  26. 8.5.1 ElectroCore Company Information
  27. 8.5.2 ElectroCore Business Overview
  28. 8.5.3 ElectroCore Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ElectroCore Endogenous Neuromodulation Platform Product Portfolio
  30. 8.5.5 ElectroCore Recent Developments
  31. 8.6 Neuronetics
  32. 8.6.1 Neuronetics Company Information
  33. 8.6.2 Neuronetics Business Overview
  34. 8.6.3 Neuronetics Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Neuronetics Endogenous Neuromodulation Platform Product Portfolio
  36. 8.6.5 Neuronetics Recent Developments
  37. 8.7 LivaNova
  38. 8.7.1 LivaNova Company Information
  39. 8.7.2 LivaNova Business Overview
  40. 8.7.3 LivaNova Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LivaNova Endogenous Neuromodulation Platform Product Portfolio
  42. 8.7.5 LivaNova Recent Developments
  43. 8.8 Magstim
  44. 8.8.1 Magstim Company Information
  45. 8.8.2 Magstim Business Overview
  46. 8.8.3 Magstim Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Magstim Endogenous Neuromodulation Platform Product Portfolio
  48. 8.8.5 Magstim Recent Developments
  49. 8.9 Sooma
  50. 8.9.1 Sooma Company Information
  51. 8.9.2 Sooma Business Overview
  52. 8.9.3 Sooma Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sooma Endogenous Neuromodulation Platform Product Portfolio
  54. 8.9.5 Sooma Recent Developments
  55. 8.10 Neuroelectrics
  56. 8.10.1 Neuroelectrics Company Information
  57. 8.10.2 Neuroelectrics Business Overview
  58. 8.10.3 Neuroelectrics Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Neuroelectrics Endogenous Neuromodulation Platform Product Portfolio
  60. 8.10.5 Neuroelectrics Recent Developments
  61. 8.11 Flow Neuroscience
  62. 8.11.1 Flow Neuroscience Company Information
  63. 8.11.2 Flow Neuroscience Business Overview
  64. 8.11.3 Flow Neuroscience Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Flow Neuroscience Endogenous Neuromodulation Platform Product Portfolio
  66. 8.11.5 Flow Neuroscience Recent Developments
  67. 8.12 ONWARD Medical
  68. 8.12.1 ONWARD Medical Company Information
  69. 8.12.2 ONWARD Medical Business Overview
  70. 8.12.3 ONWARD Medical Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ONWARD Medical Endogenous Neuromodulation Platform Product Portfolio
  72. 8.12.5 ONWARD Medical Recent Developments
  73. 8.13 PINS Medical
  74. 8.13.1 PINS Medical Company Information
  75. 8.13.2 PINS Medical Business Overview
  76. 8.13.3 PINS Medical Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  77. 8.13.4 PINS Medical Endogenous Neuromodulation Platform Product Portfolio
  78. 8.13.5 PINS Medical Recent Developments
  79. 8.14 SceneRay
  80. 8.14.1 SceneRay Company Information
  81. 8.14.2 SceneRay Business Overview
  82. 8.14.3 SceneRay Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  83. 8.14.4 SceneRay Endogenous Neuromodulation Platform Product Portfolio
  84. 8.14.5 SceneRay Recent Developments
  85. 8.15 Yingchi Technology
  86. 8.15.1 Yingchi Technology Company Information
  87. 8.15.2 Yingchi Technology Business Overview
  88. 8.15.3 Yingchi Technology Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Yingchi Technology Endogenous Neuromodulation Platform Product Portfolio
  90. 8.15.5 Yingchi Technology Recent Developments
  91. 8.16 Yiruide
  92. 8.16.1 Yiruide Company Information
  93. 8.16.2 Yiruide Business Overview
  94. 8.16.3 Yiruide Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Yiruide Endogenous Neuromodulation Platform Product Portfolio
  96. 8.16.5 Yiruide Recent Developments
  97. 8.17 Neuracle
  98. 8.17.1 Neuracle Company Information
  99. 8.17.2 Neuracle Business Overview
  100. 8.17.3 Neuracle Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Neuracle Endogenous Neuromodulation Platform Product Portfolio
  102. 8.17.5 Neuracle Recent Developments
  103. 8.18 BrainCo
  104. 8.18.1 BrainCo Company Information
  105. 8.18.2 BrainCo Business Overview
  106. 8.18.3 BrainCo Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  107. 8.18.4 BrainCo Endogenous Neuromodulation Platform Product Portfolio
  108. 8.18.5 BrainCo Recent Developments
  109. 8.19 Cyberdyne
  110. 8.19.1 Cyberdyne Company Information
  111. 8.19.2 Cyberdyne Business Overview
  112. 8.19.3 Cyberdyne Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Cyberdyne Endogenous Neuromodulation Platform Product Portfolio
  114. 8.19.5 Cyberdyne Recent Developments
  115. 8.20 Teijin Pharma
  116. 8.20.1 Teijin Pharma Company Information
  117. 8.20.2 Teijin Pharma Business Overview
  118. 8.20.3 Teijin Pharma Endogenous Neuromodulation Platform Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Teijin Pharma Endogenous Neuromodulation Platform Product Portfolio
  120. 8.20.5 Teijin Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst